

CLINICAL TRIALS

NCH is an affiliate able to participate in National Cancer Institute trials.

Reference Number	ClinicalTrials.gov NCT ID #	Trial Name	Principal Investigator	Patient Criteria
NCH 16-05 A011401	NCT02750826	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	Stephen Nigh, M.D.	Patients 18 years of age or older with a diagnosis of breast cancer stage II or stage III with BMI > 27
NCH 16-06 NRG-BR003	NCT01805076	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer	Stephen Nigh, M.D.	Patients 18 years of age or older with a diagnosis of triple-negative breast cancer
NCH 16-08 A011104/6694	NCT02488967	Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer	Stephen Nigh, M.D.	Patients 18 years of age or older with a diagnosis of breast cancer, estrogen-progesterone negative, HER2 positive or negative
NCH 17-02 NRG-GI002	NCT02921256	A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer	Urszula Sobol, M.D.	Patients 18 years of age or older with a diagnosis of locally advanced stage II or stage III rectal cancer
NCH 16-03 UC13-1235	NCT02122185	A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer	Diane Yamada, M.D.	Patients 18 years of age or older with stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma
NCH 18-12 S1418	NCT02954874	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with \geq 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy	Urszula Sobol, M.D.	Patients 18 years of age or older with a diagnosis of triple-negative breast cancer

If you are interested in learning more, contact Laura Lozano at llozano@nch.org or 847-618-4358.

